Clinical Cell Culture Ltd has won Australia Best Practices Awards for 2006 as the Biotech Vendor of the year, and also Biotech Product Innovation of the year.
Clinical Cell Culture Ltd has won Australia Best Practices Awards for 2006 as the Biotech Vendor of the year, and also Biotech Product Innovation of the year.
The awards are in recognition of the company's CellSpray technology, which is a revolutionary treatment for major burns and scars.
Cells are harvested from a small biopsy and cultured in C3's laboratory for approximately 5 to 7 days and then reapplied to the wound.
CellSpray® has regulatory approval in a number of European countries with patients currently being treated.
The accolades were awarded by Frost & Sullivan, a global growth consulting company.
C3 Managing Director Troels Jordansen said he was delighted that the achievements and progress made by C3 had been recognised by Frost & Sullivan, one of the best-regarded companies in medical and technical market research, forecasting and consulting.
"This recognition from Frost & Sullivan reaffirms C3's position as a leading tissue
engineering company which has developed and successfully launched products globally," said Mr Jordansen.
THE FULL MEDIA RELEASE APPEARS BELOW.
FRIDAY, 31 MARCH 2006
C3 RECEIVES FROST & SULLIVAN AWARDS
31 March 2006: Clinical Cell Culture Ltd (C3, ASX: CCE) is pleased to announce that
Frost & Sullivan (www.frost.com), a global growth consulting company, has awarded C3 its 2006 Australia Best Practices Award for Biotech Vendor of the year and the 2006 Australia Best Practices Award for Biotech Product Innovation of the year for CellSpray.®
CellSpray® is a suspension containing cultured skin cells for use in the treatment of major burns and scars. Cells are harvested from a small biopsy and cultured in C3's laboratory for approximately 5 to 7 days and then reapplied to the wound. CellSpray® has regulatory approval in a number of European countries with patients currently being treated.
C3 Managing Director Troels Jordansen said he was delighted that the achievements and progress made by C3 had been recognised by Frost & Sullivan, one of the best-regarded companies in medical and technical market research, forecasting and consulting.
"This recognition from Frost & Sullivan reaffirms C3's position as a leading tissue
engineering company which has developed and successfully launched products globally," said Mr Jordansen.
"We are now very focused on building sales revenue for CellSpray® and its sister products CellSpray® XP and ReCell® in major markets in which C3 has product approval."
ABOUT C3
Clinical Cell Culture (C3) is a publicly listed biomedical company that develops and distributes a number of
tissue-engineered products for the treatment of wounds and other skin defects. Using proprietary tissueculture/collection technology, C3 is able to provide innovative treatment solutions derived from the patients own skin, to enhance healing rates, reduce scar formation and reintroduce pigmentation into the skin.
PRODUCT PORTFOLIO
- C3 products use autologous cells obtained from the patients themselves to lower the risks for cross
contamination and rejection. Further, the rapid harvest and culture time has the potential to
significantly improve the rate of healing which can favourably impact the aesthetic and functional
outcome for the patient and reduce overall costs. C3 continues research into the development of new
tissue engineered products and medical devices for burn and wound healing.
- CellSpray® (www.cellspray.info) is a suspension containing cultured skin cells for use in the treatment
of major burns and scars. Cells are harvested from a small skin sample (biopsy) and cultured in C3's
laboratory over approximately 5 to 7 days. Traditional technologies take approximately 21 days to
culture small sheets of skin.
- CellSpray® XP (www.cellspray.info) is a rapid version of CellSpray® that is available within 48-hours of
a biopsy being taken. CellSpray® XP is generally applied to wounds that must be treated urgently
- ReCell® (www.recell.info) is a stand-alone, rapid cell harvesting device that enables surgeons to treat
skin defects using the patient's own cells that are collected during surgery. The surgeon can prepare
a small quantity of cells within 30 minutes on site rather than having to send a biopsy to the laboratory.
ReCell® has been designed for use in a wide variety of plastic, reconstructive and cosmetic
procedures.
Sales of all three products are now underway in several key markets, with distributors engaged to sell in
additional markets as further approvals are confirmed.
C3's products have been used on more than 2,000 cases to date and have the potential to treat millions of
patients worldwide.
PRODUCT DEVELOPMENT
C3 is currently working on a number of product development and enhancement projects. A reusable ReCell®
device is being developed which will give C3 access to price sensitive markets. An enhanced spray head is also
being developed which will enhance IP protection. New versions of Trypsin are being tested and reviewed to
further improve the performance of ReCell® and provide C3 with additional IP protection.
ReCell® APPROVED MARKETS
Argentina, Austria, Belgium, Chile, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece,
Hong Kong, Ireland, Israel, Italy, Japan, Luxembourg, Malaysia, Norway, Philippines, Poland, Portugal, Saudi
Arabia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, The Netherlands, United Kingdom
CellSpray® APPROVED MARKETS
Austria, Denmark, Germany, The Netherlands, United Kingdom
CellSpray® XP APPROVED MARKETS
Austria, Denmark, Germany, Italy, Switzerland, The Netherlands, United Kingdom